Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30238% above fair value
$4.59−0.09 (-1.89%)
Close on Nov 17, 2026Market cap $63.91MP/E –Yield –
Champions Oncology operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Champions Oncology's operating cash flow for the twelve months ending Jul 31, 2026 was -$5.56M, down 172.5% year over year. For fiscal 2026 it was -$4.47M, down 160.5% from the year before. The highest annual figure on record is $7.39M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | -$4.47M | -160.5% |
| FY2025 | Apr 30, 2025 | $7.39M | – |
| FY2024 | Apr 30, 2024 | -$6.14M | -254.5% |
| FY2023 | Apr 30, 2023 | $3.97M | -38.9% |
| FY2022 | Apr 30, 2022 | $6.50M | – |
| FY2021 | Apr 30, 2021 | -$1.68M | -157.9% |
| FY2020 | Apr 30, 2020 | $2.91M | +56.0% |
| FY2019 | Apr 30, 2019 | $1.86M | – |
| FY2018 | Apr 30, 2018 | -$1.23M | – |
| FY2017 | Apr 30, 2017 | -$2.84M | – |
| FY2016 | Apr 30, 2016 | -$6.41M | – |
| FY2015 | Apr 30, 2015 | -$9.63M | – |
| FY2014 | Apr 30, 2014 | -$3.43M | – |
| FY2013 | Apr 30, 2013 | -$4.30M | – |
| FY2012 | Apr 30, 2012 | -$5.23M | – |
| FY2011 | Apr 30, 2011 | -$54.00K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | -$492.00K | -182.0% |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | -$2.00M | -129.1% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | -$1.34M | -373.3% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | -$1.74M | – |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | $600.00K | +92.9% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | $6.87M | – |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | $490.00K | – |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | -$283.00K | -148.0% |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $311.00K | – |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | -$1.82M | – |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | -$919.00K | -158.4% |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | $589.00K | -82.1% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | -$3.99M | – |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | -$692.00K | -186.9% |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | $1.57M | -63.0% |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | $3.29M | +167.6% |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | -$195.00K | -190.3% |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | $796.00K | – |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | $4.26M | +3053.3% |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | $1.23M | +39.7% |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | $216.00K | – |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | -$1.98M | -177.8% |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | $135.00K | -51.6% |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | $879.00K | +144.2% |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | -$715.00K | – |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | $2.55M | +909.9% |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | $279.00K | -76.9% |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | $360.00K | +462.5% |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | -$279.00K | -183.0% |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | $252.00K | +2700.0% |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | $1.21M | +171.9% |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | $64.00K | -76.1% |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | $336.00K | – |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | $9.00K | -97.7% |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | $445.00K | – |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | $268.00K | +131.0% |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | -$1.95M | – |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | $398.00K | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | -$684.00K | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | $116.00K | – |
See a number that looks wrong?